Nonpayment. In the event Licensee fails to pay any undisputed amounts due and payable to WuXi Biologics hereunder, and fails to make such payments within thirty (30) days after receiving written notice of such failure, WuXi Biologics may terminate this Agreement [***] upon written notice to Licensee.
Appears in 5 contracts
Sources: Cell Line License Agreement (Glycomimetics Inc), Cell Line License Agreement (Oruka Therapeutics, Inc.), Cell Line License Agreement (Aerovate Therapeutics, Inc.)
Nonpayment. In the event Licensee fails to pay any undisputed amounts due and payable to WuXi Biologics hereunder, hereunder and fails to make such payments within thirty (30) days after receiving written notice of such failure, WuXi Biologics may terminate this Agreement [***] upon written notice to Licensee.
Appears in 1 contract
Sources: Cell Line License Agreement (Spyre Therapeutics, Inc.)